0001140859-17-000042.txt : 20171107 0001140859-17-000042.hdr.sgml : 20171107 20171107090527 ACCESSION NUMBER: 0001140859-17-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171107 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERISOURCEBERGEN CORP CENTRAL INDEX KEY: 0001140859 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 233079390 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16671 FILM NUMBER: 171181280 BUSINESS ADDRESS: STREET 1: 1300 MORRIS DRIVE CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 BUSINESS PHONE: 6107277000 MAIL ADDRESS: STREET 1: 1300 MORRIS DRIVE CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 8-K 1 abc8-knovember32017.htm 8-K Document


 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

_________________________________


FORM 8-K
_________________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

November 7, 2017
Date of Report (Date of earliest event reported)
 _________________________________
AmerisourceBergen Corporation
(Exact name of registrant as specified in its charter)
_________________________________
Delaware
 
1-16671
 
23-3079390
(State or other jurisdiction of
 
(Commission File Number)
 
(IRS Employer
incorporation)
 
 
 
Identification No.)
 
 
 
 
 
 
 
1300 Morris Drive
 
 
 
 
Chesterbrook, PA 19087
 
 
(Address of principal executive offices, including Zip Code)

(610) 727-7000
(Registrant’s telephone number, including area code) 

Not Applicable
(Former name or former address, if changed since last report.)
_________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2of this chapter).

Emerging Growth Company o  

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
 
 





Item 7.01    Regulation FD Disclosure.

Effective September 30, 2017, AmerisourceBergen Corporation (the "Company") combined the legacy AmerisourceBergen Drug Corporation and AmerisourceBergen Specialty Group operating segments into a single operating segment, Pharmaceutical Distribution Services. In addition, in connection with the completion of this reorganization, the Company's non-title third party logistics business, which was included within the Pharmaceutical Distribution Services reportable segment, was combined with the World Courier operating segment in Other, while the AmerisourceBergen Consulting Services distribution business (previously included in Other) is now included in the Pharmaceutical Distribution Services reportable segment. The Company revised its previously-reported segment disclosures to reflect the aforementioned changes to its reporting structure. These changes did not have a material impact to its historical reportable segment operating results.

In the attached Exhibit 99.1, which is incorporated herein by reference, the Company is voluntarily furnishing a supplemental disclosure of unaudited revised reportable segment information prepared on the same basis that the Company reported the fiscal quarter ended September 30, 2017 for (a) the first, second and third fiscal quarters of fiscal 2017, and each fiscal quarter of fiscal 2016 and (b) the fiscal year ended September 30, 2016 to assist investors in analyzing the changes to its reporting structure.
 
The information contained in this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.







Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits.

The following exhibit is being furnished as part of this report:






SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
AMERISOURCEBERGEN CORPORATION
 
 
Date: November 7, 2017
By:
/s/ Tim G. Guttman
 
Name:
Tim G. Guttman
 
Title:
Executive Vice President & Chief Financial Officer
 
 
 



 EX-99.1 2 exhibit991.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(in thousands)
(unaudited)

The following illustrates revised reportable segment revenue information for the periods indicated:
 
 
Fiscal Year Ended September 30, 2017
Revenue
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Fiscal Year
 
 
(As Revised)
 
(As Revised)
 
(As Revised)
 
 
 
 
Pharmaceutical Distribution Services
 
$
36,798,288

 
$
35,745,361

 
$
37,255,195

 
$
37,654,651

 
$
147,453,495

Other
 
1,384,490

 
1,415,850

 
1,467,536

 
1,479,987

 
5,747,863

Intersegment eliminations
 
(13,513
)
 
(13,809
)
 
(15,587
)
 
(14,623
)
 
(57,532
)
Revenue
 
$
38,169,265

 
$
37,147,402

 
$
38,707,144

 
$
39,120,015

 
$
153,143,826

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year Ended September 30, 2016
Revenue
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Fiscal Year
 
 
(As Revised)
 
(As Revised)
 
(As Revised)
 
(As Revised)
 
(As Revised)
Pharmaceutical Distribution Services
 
$
35,440,095

 
$
34,420,594

 
$
35,583,985

 
$
36,257,323

 
$
141,701,997

Other
 
1,280,620

 
1,291,322

 
1,315,545

 
1,319,608

 
5,207,095

Intersegment eliminations
 
(11,669
)
 
(13,559
)
 
(17,850
)
 
(16,328
)
 
(59,406
)
Revenue
 
$
36,709,046

 
$
35,698,357

 
$
36,881,680

 
$
37,560,603

 
$
146,849,686











AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
    
The following illustrates revised reportable segment operating income information for the periods indicated:
 
 
Fiscal Year Ended September 30, 2017
Operating income
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Fiscal Year
 
 
(As Revised)
 
(As Revised)
 
(As Revised)
 
 
 
 
Pharmaceutical Distribution Services
 
$
379,060

 
$
484,878

 
$
379,976

 
$
399,715

 
$
1,643,629

Other
 
107,148

 
103,593

 
91,338

 
71,718

 
373,797

Intersegment eliminations
 
(13
)
 
(1
)
 
(198
)
 
(344
)
 
(556
)
Total segment operating income
 
$
486,195

 
$
588,470

 
$
471,116

 
$
471,089

 
$
2,016,870

 
 
 
 
 
 
 
 
 
 
 
Percentages of revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmaceutical Distribution Services
 
 
 
 
 
 
 
 
 
 
Gross profit
 
2.05%
 
2.42%
 
2.03%
 
2.14%
 
2.16%
Operating expenses
 
1.02%
 
1.07%
 
1.01%
 
1.07%
 
1.04%
Operating income
 
1.03%
 
1.36%
 
1.02%
 
1.06%
 
1.11%
 
 
 
 
 
 
 
 
 
 
 
Other
 
 
 
 
 
 
 
 
 
 
Gross profit
 
22.36%
 
21.49%
 
20.26%
 
19.82%
 
20.96%
Operating expenses
 
14.63%
 
14.17%
 
14.03%
 
14.97%
 
14.45%
Operating income
 
7.74%
 
7.32%
 
6.22%
 
4.85%
 
6.50%

 
 
Fiscal Year Ended September 30, 2016
Operating income
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Fiscal Year
 
 
(As Revised)
 
(As Revised)
 
(As Revised)
 
(As Revised)
 
(As Revised)
Pharmaceutical Distribution Services
 
$
385,629

 
$
502,967

 
$
416,096

 
$
398,033

 
$
1,702,725

Other
 
91,190

 
91,154

 
79,146

 
66,256

 
327,746

Intersegment eliminations
 
—

 
—

 
—

 
(103
)
 
(103
)
Total segment operating income
 
$
476,819

 
$
594,121

 
$
495,242

 
$
464,186

 
$
2,030,368

 
 
 
 
 
 
 
 
 
 
 
Percentages of revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmaceutical Distribution Services
 
 
 
 
 
 
 
 
 
 
Gross profit
 
2.18%
 
2.56%
 
2.23%
 
2.16%
 
2.28%
Operating expenses
 
1.09%
 
1.10%
 
1.06%
 
1.06%
 
1.08%
Operating income
 
1.09%
 
1.46%
 
1.17%
 
1.10%
 
1.20%
 
 
 
 
 
 
 
 
 
 
 
Other
 
 
 
 
 
 
 
 
 
 
Gross profit
 
21.89%
 
22.15%
 
20.80%
 
20.19%
 
21.25%
Operating expenses
 
14.77%
 
15.09%
 
14.78%
 
15.17%
 
14.95%
Operating income
 
7.12%
 
7.06%
 
6.02%
 
5.02%
 
6.29%